CY1109225T1 - ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣ - Google Patents
ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣInfo
- Publication number
- CY1109225T1 CY1109225T1 CY20091100729T CY091100729T CY1109225T1 CY 1109225 T1 CY1109225 T1 CY 1109225T1 CY 20091100729 T CY20091100729 T CY 20091100729T CY 091100729 T CY091100729 T CY 091100729T CY 1109225 T1 CY1109225 T1 CY 1109225T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lower alkyl
- group
- halogen
- hydrogen
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η εφεύρεση σχετίζεται με παράγωγα μηλοναμιδίου του τύπου (I), όπου: R1 είναι μία από τις ακόλουθες ομάδες (Τύποι α), b), c), d)), R2 είναι κατώτερη αλκυλομάδα, κατώτερη αλκινυλομάδα, -(CΗ2)n-O-κατώτερη αλκυλομάδα, -(CΗ2)n-S-κατώτερη αλκυλομάδα, -(CH2)n-CN,-(CR'R")n-CF3, -(CR'R")n-CHF2, -(CR'R")n-CH2F, -(CH2)n-C(O)O-κατώτερη αλκυλομάδα, -(CΗ2)n-αλογόνο, ή είναι -(CΗ2)n-κυκλοαλκυλομάδα, προαιρετικά υποκατεστημένη με έναν ή περισσότερους υποκατάστατες επιλεγμένους από την ομάδα η οποία αποτελείται από φαινυλομάδα, αλογόνο ή CF3, R', R" είναι ανεξάρτητα από το n και ανεξάρτητα μεταξύ τους υδρογόνο, κατώτερη αλκυλομάδα, κατώτερη αλκοξυομάδα, αλογόνο ή υδροξυομάδα, R3, R4 είναι ανεξάρτητα μεταξύ τους υδρογόνο, κατώτερη αλκυλομάδα, κατώτερη αλκοξυομάδα, φαινυλομάδα ή αλογόνο, R5 είναι υδρογόνο, κατώτερη αλκυλομάδα, -(CΗ2)n-CF3 ή -(CH2)n-κυκλοαλκυλομάδα, R6 είναι υδρογόνο ή αλογόνο, R7 είναι υδρογόνο ή κατώτερη αλκυλομάδα, R8 είναι υδρογόνο, κατώτερη αλκυλομάδα, κατώτερη αλκινυλομάδα, -(CΗ2)n-CF3, -(CΗ2)n-κυκλοαλκυλομάδα ή -(CΗ2)n-φαινυλομάδα, προαιρετικά υποκατεστημένη με αλογόνο, R9 είναι υδρογόνο, κατώτερη αλκυλομάδα, -C(O)H, -C(O)-κατώτερη αλκυλομάδα, -C(O)-CF3, -C(O)-CH2F, -C(Ο)-CHF2,-C(Ο)-κυκλοαλκυλομάδα,-C(Ο)-(CH2)n-Ο-κατώτερη αλκυλομάδα, -C(O)O-(CΗ2)n -κυκλοαλκυλομάδα, -C(O)-φαινυλομάδα, προαιρετικά υποκατεστημένη με έναν ή περισσότερους υποκατάστατες επιλεγμένους από την ομάδα η οποία αποτελείται από αλογόνο ή -C(O)O-κατώτερη αλκυλομάδα, ή είναι -S(O)2-κατώτερη αλκυλομάδα, -S(O)2-CF3, -(CΗ2)n -κυκλοαλκυλομάδα ή είναι -(CΗ2)n -φαινυλομάδα, προαιρετικά υποκατεστημένη με αλογόνο, n είναι 0, 1, 2, 3 ή 4, και με φαρμακευτικώς κατάλληλα άλατα προσθήκης οξέος, οπτικώς αμιγή εναντιομερή, ρακεμικά μείγματα ή μείγματα διαστερεομερών αυτών. Αυτές οι ενώσεις μπορούν να χρησιμοποιηθούν για την θεραπευτική αντιμετώπιση της νόσου Αλτσχάιμερ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03019683 | 2003-09-09 | ||
| EP04764665A EP1711470B1 (en) | 2003-09-09 | 2004-08-31 | Malonamide derivatives blocking the activtiy of gamma-secretase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109225T1 true CY1109225T1 (el) | 2014-07-02 |
Family
ID=34224068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100729T CY1109225T1 (el) | 2003-09-09 | 2009-07-10 | ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣ |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7160875B2 (el) |
| EP (1) | EP1711470B1 (el) |
| JP (2) | JP4571639B2 (el) |
| KR (3) | KR100838852B1 (el) |
| CN (1) | CN100593539C (el) |
| AR (1) | AR045609A1 (el) |
| AT (1) | ATE428698T1 (el) |
| AU (1) | AU2004270361B2 (el) |
| BR (1) | BRPI0413533A (el) |
| CA (1) | CA2537440C (el) |
| CO (1) | CO5660268A2 (el) |
| CR (1) | CR8264A (el) |
| CY (1) | CY1109225T1 (el) |
| DE (1) | DE602004020680D1 (el) |
| DK (1) | DK1711470T3 (el) |
| EA (1) | EA009940B1 (el) |
| EC (1) | ECSP066414A (el) |
| ES (1) | ES2322652T3 (el) |
| HK (1) | HK1099014A1 (el) |
| HR (1) | HRP20090266T1 (el) |
| IL (1) | IL173905A (el) |
| MA (1) | MA28034A1 (el) |
| MX (1) | MXPA06002562A (el) |
| MY (1) | MY141308A (el) |
| NO (1) | NO20061047L (el) |
| NZ (1) | NZ545538A (el) |
| PL (1) | PL1711470T3 (el) |
| PT (1) | PT1711470E (el) |
| RS (1) | RS20060146A (el) |
| SI (1) | SI1711470T1 (el) |
| TN (1) | TNSN06077A1 (el) |
| TW (1) | TW200519092A (el) |
| UA (1) | UA83501C2 (el) |
| WO (1) | WO2005023772A1 (el) |
| ZA (1) | ZA200601989B (el) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514267C (en) * | 2003-02-04 | 2011-05-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| DK1711470T3 (da) * | 2003-09-09 | 2009-06-08 | Hoffmann La Roche | Malonamidderivater der blokerer aktiviteten af gamma-sekretase |
| CA2541470C (en) * | 2003-10-06 | 2011-11-29 | F.Hoffmann-La Roche Ag | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
| US7211573B2 (en) * | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| CN101410378B (zh) * | 2006-03-27 | 2012-12-05 | 霍夫曼-拉罗奇有限公司 | 作为γ分泌酶抑制剂的丙二酰胺衍生物 |
| EP2069317A2 (en) | 2006-09-20 | 2009-06-17 | F. Hoffmann-Roche AG | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| EP2109604A1 (en) * | 2007-02-02 | 2009-10-21 | F. Hoffmann-Roche AG | 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives |
| CN101636378A (zh) * | 2007-03-15 | 2010-01-27 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽拮抗剂的丙二酰胺类 |
| US7579464B2 (en) * | 2007-05-25 | 2009-08-25 | Hoffmann-La Roche Inc. | Process for preparation of enantiomerically pure compounds |
| EP2244713A1 (en) * | 2008-01-11 | 2010-11-03 | F. Hoffmann-La Roche AG | Use of a gamma-secretase inhibitor for treating cancer |
| US8741889B2 (en) | 2008-01-11 | 2014-06-03 | Hoffmann-La Roche Inc | Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor |
| US8309299B2 (en) | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| KR101330184B1 (ko) | 2010-10-15 | 2013-11-15 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| WO2012050370A2 (ko) * | 2010-10-15 | 2012-04-19 | 성균관대학교산학협력단 | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 |
| US20120114638A1 (en) | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
| US20120184529A1 (en) | 2011-01-14 | 2012-07-19 | Demario Mark D | Combination therapy |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2897938B1 (en) | 2012-09-21 | 2017-03-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| JP2015533811A (ja) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物 |
| US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
| US9242941B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| US9427442B2 (en) | 2012-09-21 | 2016-08-30 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds |
| CN104968648A (zh) | 2012-09-21 | 2015-10-07 | 百时美施贵宝公司 | 1,4-苯并二氮杂*酮化合物的前药 |
| JP2016515625A (ja) | 2013-04-04 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 増殖性疾患を治療するための併用療法 |
| EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| KR102130458B1 (ko) * | 2015-10-30 | 2020-07-08 | 파이프라인 테라퓨틱스, 아이엔씨. | 디벤조 아제핀 화합물 및 귀 질환과 귀 장애 치료에서의 그의 용도 |
| WO2018111926A2 (en) * | 2016-12-16 | 2018-06-21 | Inception 3, Inc. | Methods of treating cochlear synaptopathy |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3668844A1 (en) * | 2017-08-15 | 2020-06-24 | Bayer Aktiengesellschaft | 4-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepine-7-carboxamides |
| MA52785A (fr) | 2018-06-01 | 2021-04-14 | Novartis Ag | Molécules de liaison dirigées contre bcma et leurs utilisations |
| KR20220024729A (ko) | 2019-06-24 | 2022-03-03 | 노파르티스 아게 | B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법 |
| WO2022020658A1 (en) * | 2020-07-23 | 2022-01-27 | Purdue Research Foundation | Notch signaling inhibitors for treating obesity and metabolic disorders |
| MX2024002599A (es) * | 2021-08-31 | 2024-03-22 | Basf Se | Malonamidas herbicidas que contienen un sistema de anillos condensados. |
| CN116621721A (zh) * | 2023-04-12 | 2023-08-22 | 珠海市柏瑞医药科技有限公司 | 一种壬二酰胺的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632812B2 (en) * | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| CA2514267C (en) * | 2003-02-04 | 2011-05-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| DK1711470T3 (da) * | 2003-09-09 | 2009-06-08 | Hoffmann La Roche | Malonamidderivater der blokerer aktiviteten af gamma-sekretase |
-
2004
- 2004-08-31 DK DK04764665T patent/DK1711470T3/da active
- 2004-08-31 CN CN200480032641A patent/CN100593539C/zh not_active Expired - Lifetime
- 2004-08-31 PL PL04764665T patent/PL1711470T3/pl unknown
- 2004-08-31 EA EA200600503A patent/EA009940B1/ru not_active IP Right Cessation
- 2004-08-31 AT AT04764665T patent/ATE428698T1/de active
- 2004-08-31 UA UAA200602854A patent/UA83501C2/uk unknown
- 2004-08-31 DE DE602004020680T patent/DE602004020680D1/de not_active Expired - Lifetime
- 2004-08-31 AU AU2004270361A patent/AU2004270361B2/en not_active Ceased
- 2004-08-31 JP JP2006525701A patent/JP4571639B2/ja not_active Expired - Lifetime
- 2004-08-31 PT PT04764665T patent/PT1711470E/pt unknown
- 2004-08-31 CA CA2537440A patent/CA2537440C/en not_active Expired - Fee Related
- 2004-08-31 KR KR1020077017457A patent/KR100838852B1/ko active IP Right Grant
- 2004-08-31 BR BRPI0413533-4A patent/BRPI0413533A/pt not_active Application Discontinuation
- 2004-08-31 ES ES04764665T patent/ES2322652T3/es not_active Expired - Lifetime
- 2004-08-31 NZ NZ545538A patent/NZ545538A/en not_active IP Right Cessation
- 2004-08-31 KR KR1020077017458A patent/KR20070087233A/ko not_active Application Discontinuation
- 2004-08-31 WO PCT/EP2004/009700 patent/WO2005023772A1/en active Application Filing
- 2004-08-31 KR KR1020067004763A patent/KR100834177B1/ko active IP Right Grant
- 2004-08-31 EP EP04764665A patent/EP1711470B1/en not_active Expired - Lifetime
- 2004-08-31 SI SI200431116T patent/SI1711470T1/sl unknown
- 2004-08-31 MX MXPA06002562A patent/MXPA06002562A/es active IP Right Grant
- 2004-08-31 RS YUP-2006/0146A patent/RS20060146A/sr unknown
- 2004-09-02 US US10/933,177 patent/US7160875B2/en active Active
- 2004-09-06 TW TW093126876A patent/TW200519092A/zh unknown
- 2004-09-06 MY MYPI20043603A patent/MY141308A/en unknown
- 2004-09-08 AR ARP040103214A patent/AR045609A1/es not_active Application Discontinuation
-
2006
- 2006-02-23 CO CO06018272A patent/CO5660268A2/es not_active Application Discontinuation
- 2006-02-23 IL IL173905A patent/IL173905A/en active IP Right Grant
- 2006-03-01 CR CR8264A patent/CR8264A/es not_active Application Discontinuation
- 2006-03-03 NO NO20061047A patent/NO20061047L/no not_active Application Discontinuation
- 2006-03-07 TN TNP2006000077A patent/TNSN06077A1/fr unknown
- 2006-03-07 EC EC2006006414A patent/ECSP066414A/es unknown
- 2006-03-08 ZA ZA200601989A patent/ZA200601989B/en unknown
- 2006-03-10 MA MA28867A patent/MA28034A1/fr unknown
-
2007
- 2007-05-21 HK HK07105326.7A patent/HK1099014A1/xx not_active IP Right Cessation
-
2009
- 2009-05-12 HR HR20090266T patent/HRP20090266T1/xx unknown
- 2009-07-10 CY CY20091100729T patent/CY1109225T1/el unknown
-
2010
- 2010-06-18 JP JP2010138970A patent/JP2010229153A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109225T1 (el) | ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣ | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| CY1116865T1 (el) | Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| CO5670367A2 (es) | Derivados de acido fenoxiacetico | |
| CY1105899T1 (el) | Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες | |
| NO20085160L (no) | Nye glucokinaseaktivatorer og deres anvendelse | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| CY1111271T1 (el) | Παραγωγο τριαζολονης | |
| MXPA01004854A (es) | Nuevos compuestos de piperazina y piperidina. | |
| ATE180780T1 (de) | 2-(piperidin-4-yl, pyridin-4-yl und tetrahydropyridin-4-yl)-benzofuran-7-carbamat derivate, ihre herstellung und verwendung als acetylcholinesterase inhibitoren | |
| CY1107206T1 (el) | Παραγωγα οξαζολιου/θειαζολιου ενεργοποιητες του υποδοχεα hppar-a | |
| DK0754682T3 (da) | Aminostilbazolderivat og lægemiddel | |
| PE20030705A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes | |
| NO20062936L (no) | Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav | |
| AR037698A1 (es) | N-[4-(1h-imidazol-1-il)-2-fluorofenil]-3-(trifluorometil)-1h-pirazol-5-carboxamidas como inhibidores del factor xa | |
| ATE95816T1 (de) | 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung. | |
| DE60002558D1 (de) | Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B | |
| TR200100660T2 (tr) | Piperidin türevleri. | |
| FI912903A (fi) | Nya n-benzyl-n1-fenyl- och fenylalkyl -tiourea-foereningar. | |
| RU2008103452A (ru) | Фторзамещенные производные 2-оксо-азепана | |
| EA201000666A1 (ru) | Производные 5-замещенных индол-3-карбоновой кислоты, обладающие противовирусной активностью, способ их получения и применение | |
| HUP0203365A2 (hu) | Rinovírus proteáz inhibitorok szintetikus előállítási eljárása és az eljárás köztitermékei | |
| ATE28639T1 (de) | Derivate von 4-(3-alkynyloxy-2-hydroxy-propyl)piperazin-1-yl-n-phenylacetamid, ihre herstellung und ihre therapeutische verwendung. | |
| ES2037833T3 (es) | 2-amino-5-hidroxi-4-pirimidonas. |